adamas
announces
settlement
agreement
previously
disclosed
class
action
litigation
emeryville
globe
newswire
adamas
pharmaceuticals
nasdaq
adms
company
dedicated
developing
delivering
medicines
make
meaningful
difference
people
affected
neurological
diseases
today
announced
signed
memorandum
understanding
settle
one
previously
disclosed
securities
lawsuits
plymouth
adamas
pharmaceuticals
et
case
pending
california
superior
court
county
alameda
proposed
settlement
calls
payment
million
eligible
settlement
class
members
resolution
claims
asserted
company
officers
directors
defendants
settlement
paid
adamas
director
officer
liability
insurance
adamas
defendants
continue
deny
plaintiff
claims
liability
adamas
agreed
settlement
resolve
disputes
avoid
costs
risks
litigation
avoid
distractions
management
settlement
remains
subject
final
documentation
approval
court
final
closure
court
action
expected
adamas
pharmaceuticals
adamas
purpose
vision
clear
deliver
innovative
medicines
make
clinically
meaningful
difference
patients
caregivers
society
fully
integrated
company
focused
growing
portfolio
therapies
address
range
neurological
diseases
information
please
visit
statements
statements
contained
press
release
regarding
matters
may
occur
future
statements
within
meaning
private
securities
litigation
reform
act
including
limited
statements
contained
press
release
regarding
adamas
expectations
described
settlement
agreement
statements
subject
risks
uncertainties
actual
results
may
differ
materially
expressed
implied
statements
particular
settlement
agreement
agreement
principal
subject
court
approval
description
risks
relating
adamas
business
general
see
adamas
quarterly
report
form
filed
securities
exchange
commission
august
particularly
caption
risk
investors
cautioned
place
undue
reliance
statements
speak
date
release
adamas
undertakes
obligation
update
statement
press
release
except
required
law
contact
